AAA
ASND icon

Affinity Asset Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Affinity Asset Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$2.58M – 70
2021
Q1 		$2.58M Buy
+20,000
New +$3.04M 0.88% 32

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Affinity Asset Advisors's ASND Position: Q1 2026 in Review

Affinity Asset Advisors increased its Ascendis Pharma A/S (ASND) stake by 217% in Q1 2026, buying an estimated $14.6M and bringing the position to 95,000 shares worth $21.7M. The position accounts for 1.12% of the portfolio, ranked #29.

Affinity Asset Advisors first reported a position in ASND in Q4 2020 and has held it in 14 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Affinity Asset Advisors held 95,000 shares of Ascendis Pharma A/S worth $21.7M as of Q1 2026.
  • Affinity Asset Advisors bought 65,000 Ascendis Pharma A/S shares in Q1 2026, an estimated $14.6M.
  • Ascendis Pharma A/S made up 1.12% of Affinity Asset Advisors's portfolio in Q1 2026, its #29 holding.
  • Affinity Asset Advisors first reported a position in Ascendis Pharma A/S in Q4 2020 and has held it in 14 quarters since.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.